Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
CCEL
Cryo-Cell International, Inc.
Cryo-Cell's core business is private cord blood and cord tissue stem cell collection, processing, and long-term cryogenic storage, aligning with the Biotech - Cell Therapy investable theme.
|
$27.71M |
$3.51
-3.04%
|
|
MRKR
Marker Therapeutics, Inc.
Marker Therapeutics develops MAR-T cell therapies, a cell-based immunotherapy platform targeting cancer.
|
$27.68M |
$1.68
+4.35%
|
|
NXTC
NextCure, Inc.
NextCure's lead programs are Antibody-Drug Conjugates (ADCs), the core product modality of the company.
|
$27.67M |
$10.28
-6.55%
|
|
TELA
TELA Bio, Inc.
TELA Bio manufactures OviTex Reinforced Tissue Matrix, a medical device/biomaterial used in soft tissue reconstruction, aligning with Medical Devices & Biometrics.
|
$27.55M |
$0.68
-7.19%
|
|
HBIO
Harvard Bioscience, Inc.
HBIO generates recurring revenue from consumables used with its medical devices and bioproduction platforms (biochips, reagents, etc.).
|
$27.33M |
$6.08
+2.88%
|
|
RNTX
Rein Therapeutics Inc.
IPF/related fibrotic orphan indications classify Rein's lead assets as addressing a rare disease space.
|
$26.57M |
$1.16
-3.33%
|
|
AYTU
Aytu BioPharma, Inc.
AYTU's core ADHD portfolio comprises oral small-molecule therapeutics (Adzenys XR-ODT, Cotempla XR-ODT) and Karbinal ER, fitting the 'Oral Small Molecule Therapeutics' category.
|
$26.49M |
$2.59
+0.39%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$25.63M |
$1.02
+4.06%
|
|
SKYE
Skye Bioscience, Inc.
Nimacimab is a monoclonal antibody therapeutic targeting CB1, making Monoclonal Antibody Therapeutics the direct product category.
|
$25.29M |
$0.79
+5.08%
|
|
KPEA
Kun Peng International Ltd.
The business includes health care equipment-based services and devices, aligning with medical devices & equipment.
|
$24.96M |
$0.06
|
|
SNTI
Senti Biosciences, Inc.
Directly develops cancer therapies and immuno-oncology agents, notably SENTI-202 CAR-NK therapies targeting AML.
|
$24.91M |
$0.95
+0.14%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$24.82M |
$11.46
-3.25%
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$24.79M |
$0.64
+5.52%
|
|
FEMY
Femasys Inc.
Femasys manufactures medical devices and biometrics for women's reproductive health (FemBloc, FemaSeed, FemVue, etc.).
|
$24.79M |
$0.42
+0.36%
|
|
ICCM
IceCure Medical Ltd
IceCure manufactures liquid nitrogen-based cryoablation medical devices (ProSense/XSEN) used for tumor destruction, i.e., medical devices & biometrics.
|
$24.76M |
$0.35
-2.51%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
Ketamir-2 is a novel oral small-molecule therapeutic targeting neuropathic pain, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$24.22M |
$1.25
-1.97%
|
|
XCUR
Exicure, Inc.
GPCR USA's lead asset GPC-100.00 is an oncology biotech product in development, representing the core biotech asset.
|
$24.14M |
$3.77
-2.28%
|
|
BRNS
Barinthus Biotherapeutics plc
Company is pivoting to immunology/inflammation therapeutics and is advancing T‑cell immunotherapies (SNAP-TI), with VTP-1000 for celiac disease as lead candidate.
|
$24.09M |
$0.62
+4.91%
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$23.83M |
$4.74
-5.58%
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$23.64M |
$1.70
-9.57%
|
|
LGVN
Longeveron Inc.
LGVN's lead candidate laromestrocel is a mesenchymal stem cell (MSC) therapy, directly aligning with Biotech - Cell Therapy.
|
$23.47M |
$1.09
-0.45%
|
|
MLSS
Milestone Scientific Inc.
Direct dental equipment manufacturing (DPS-based systems and related dental devices) as the dental segment is a core business.
|
$22.55M |
$0.29
-0.66%
|
|
NWBO
Northwest Biotherapeutics, Inc.
NWBO is a cancer-focused biotechnology company developing oncology immunotherapies (DCVax) and related products; tags align with Biotech - Oncology.
|
$22.35M |
$0.20
|
|
UEEC
United Health Products, Inc.
CelluSTAT is a surgical hemostatic device used in operative settings, categorizing the company as a Surgical Equipment manufacturer.
|
$21.99M |
$0.08
|
|
WETH
Wetouch Technology Inc.
Medical applications revenue suggests involvement as a component provider in medical devices, i.e., Medical Device Components.
|
$21.83M |
$1.81
+13.84%
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$20.88M |
$0.86
-3.23%
|
|
COCP
Cocrystal Pharma, Inc.
Cocrystal Pharma is actively developing antiviral small-molecule therapeutics (CC-42344, CDI-988, CC-31244) for influenza, norovirus/coronavirus, and HCV.
|
$20.81M |
$1.51
-3.82%
|
|
LIXT
Lixte Biotechnology Holdings, Inc.
LB-100 is Lixte's lead oncology drug candidate (PP2A inhibitor) being developed for cancer therapy, constituting the primary product/offerable asset.
|
$20.59M |
$3.63
+12.73%
|
|
COCH
Envoy Medical, Inc.
Envoy Medical designs and manufactures implantable medical devices with biometric sensing capabilities (Acclaim CI and Esteem FI-AMEI).
|
$20.40M |
$0.70
-0.76%
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$20.35M |
$0.28
-31.68%
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$20.16M |
$0.61
-1.05%
|
|
RVP
Retractable Technologies, Inc.
Core product category directly manufactured and sold: passive-safety syringes designed to prevent needlestick injuries.
|
$20.06M |
$0.68
-2.10%
|
|
OTLK
Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA is a regulatory-approved ophthalmic formulation of bevacizumab for intravitreal use.
|
$19.82M |
$0.31
+14.98%
|
|
ALLR
Allarity Therapeutics, Inc.
DRP platform functions as a companion diagnostic to identify patients likely to respond to stenoparib and other therapies.
|
$19.45M |
$1.22
-1.61%
|
Showing page 31 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
